Fondation Prévenir le Cancer^® awards nine new research grants

POUR DIFFUSION IMMÉDIATE
Contact: Lisa Berry Edwards
703-519-2107
Lisa.Edwards@preventcancer.org

Alexandria, VA—The Prevent Cancer Foundation is pleased to announce funding for nine scientists who are researching cancer prevention and early detection. Each scientist is being awarded $100,000 for two years. Areas of focus include the pancreas, esophagus, liver, lungs, skin, prostate, colon-rectum, and blood/bone marrow.

Here are the 2021 research grantees. Click here for more detailed information on their projects.

Bénéficiaire:  Limor Appelbaum, M.D.
Prix nommé : Des jeux géniaux réalisés rapidement
Position: Staff Scientist
Institution: Beth Israel Deaconess Medical Center, Boston, MA
Titre du projet: Use of medical records and microbiome for predicting pancreatic cancer

Pancreatic cancer is usually diagnosed in advanced stages when cure is no longer possible. Early detection of this cancer can lead to cure. Dr. Appelbaum proposes a model that can identify people at high risk of pancreatic cancer to be recommended for screening, which can potentially save lives.

Bénéficiaire: Julie A. Barta, M.D., A.T.S.F.
Prix nommé : Prix Richard C. Devereaux du jeune chercheur exceptionnel
Position: Assistant Professor of Medicine
Institution: Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA
Application Title: Improving lung cancer screening barriers for vulnerable populations

Despite the advent of lung screening to identify cancers at early, curable stages, major disparities exist in screening uptake and adherence. This project will examine and alleviate financial and technological barriers for vulnerable populations to increase lung cancer early detection and survival rates.

Bénéficiaire: Neil Box, Ph.D.
Position: professeur agrégé
Institution: University of Colorado Denver, Anschutz Medical Campus and Denver Campus, Denver, CO
Titre du projet: Integrating sun damage indicators in melanoma risk modeling

Dr. Box and his team will study how skin damaged by ultraviolet radiation can predict melanoma risk in children of certain genetic makeup. Their work will identify high-risk groups and prove the value of our tools in personalized melanoma prediction and prevention.

Bénéficiaire: Sigrid Carlsson, M.D., Ph.D., M.P.H.
Prix nommé : Des jeux géniaux réalisés rapidement
Position: Assistant épidémiologiste traitant
Institution: Memorial Sloan Kettering Cancer Center, New York, NY
Application Title: Improving prostate cancer screening using innovative technology

Dr. Carlsson and her team developed an innovative computer technology to help primary care physicians use “smarter” screening for prostate cancer for men who are most likely to benefit. The aim of this study is to test the usefulness of this computerized decision support tool in a large primary care network.

Bénéficiaire: Margie Clapper, Ph.D.
Position: Deputy Scientific Director/Professor/Co-Leader, Cancer Prevention and Control Program
Institution: The Research Institute of Fox Chase Cancer Center, Philadelphia, PA
Titre du projet: Impact of atorvastatin with or without aspirin on colorectal biomarkers in patients with Lynch Syndrome: a pilot study

Lynch Syndrome (LS) is the most common genetic cause of colon cancer in people under age 50. Atorvastatin reduces colon microadenomas dramatically in mice. Understanding the effect of atorvastatin with or without aspirin on colon biomarkers is critical to developing a preventive therapy for LS patients.

Bénéficiaire: William Grady, M.D.
Prix nommé : La Fondation caritative de la famille Shure
Position: Professor
Institution: Fred Hutchinson Cancer Research Center, Seattle, WA
Titre du projet: Dysbiotic esophageal microbiomes and esophageal cancer risk

These studies have the potential to identify cancer-causing esophageal bacteria, which could lead to novel and improved ways to prevent cancer through more accurate cancer risk prediction. The studies could also lead to novel antibiotic or probiotic cancer prevention treatments for esophageal cancer.

Fellow: Natalia Heredia, Ph.D., M.P.H.
Position: Maître assistant
Institution: The University of Texas Health Science Center, Houston, TX 
Prix nommé : Fondation caritative Marcia et Frank Carlucci
Titre du projet: Culturally tailored lifestyle intervention for Hispanic non-alcoholic fatty liver disease

The rate of new cases of liver cancer continues to increase in Hispanics, partially due to a condition called non-alcoholic fatty liver disease (NAFLD). Treatment for NAFLD includes weight loss, so by helping Hispanic NAFLD patients lose weight, we can prevent future cases of NAFLD-related liver cancer.

Bénéficiaire: Maro Ohanian, D.O.
Prix nommé: Triad Foundation, LLC
Position: Maître assistant
Institution: University of Texas M.D. Anderson Cancer Center, Houston, TX
Titre du projet: Detoxification of environmental metals to prevent acute myeloid leukemia

Toxic metals are a modifiable risk factor associated with increased cancer risk. Dr. Ohanian aims to reverse carcinogenic effects of environmental/occupational metal exposures that can lead to acute myeloid leukemia (AML) by detoxifying metals in patients with myelodysplastic syndrome (pre-leukemia) as a novel cancer prevention method.

Fellow: Aayushi Uberoi, Ph.D.
Prix nommé : Des jeux géniaux réalisés rapidement
Position: Postdoctoral Scholar
Institution: University of Pennsylvania, Philadelphia, PA
Titre du projet: Modulating skin microbiota-host interactions to prevent UV-induced skin cancer

While the skin microbiome encounters the same ultraviolet B (UVB) exposure as the skin, the effects of UVB on the skin microbiome is unexplored. By exploring host-microbiome interactions during UVB-associated skin cancers, we can uncover a novel class of biomarkers and therapeutics for prevention of skin cancer.

À propos de la Fondation Prévenir le Cancer^®

La Fondation Prévenir le Cancer^® is celebrating 35 years as the only U.S. nonprofit organization focused solely on saving lives across all populations through cancer prevention and early detection.  Through research, education, outreach and advocacy, we have helped countless people avoid a cancer diagnosis or detect their cancer early enough to be successfully treated.

La Fondation se mobilise pour relever le défi de réduire les décès par cancer de 40% d'ici 2035. Pour y parvenir, nous nous engageons à investir $20 millions dans des technologies innovantes pour détecter le cancer à un stade précoce et faire progresser le dépistage multi-cancer, $10 millions pour étendre le dépistage du cancer et la vaccination. l'accès à des communautés médicalement mal desservies et $10 millions pour informer le public sur les options de dépistage et de vaccination.

Pour plus d'informations, s'il vous plaît visitez www.preventcancer.org.